2 Senior Advisors Services for the NINDS Blueprint Neurotherapeutic Network for Small Molecules External Oversight Committee (EOC) Subject Matter Expert (SME) Services

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

OMAS STRATEGIC BUYING CENTER - PROFESSIONAL SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

7571PS27Q00021

NAICS

541690 - Other Scientific and Technical Consulting Services

Classification Code

R499

Additional Details
Set Aside

SBA

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
The Department of Health and Human Services (HHS), through its Office of the Assistant Secretary for Financial Resources (ASFR) and the OMAS Strategic Buying Center – Professional Services, has issued a combined synopsis/solicitation for the procurement of two Senior Advisor Subject Matter Expert (SME) services. This requirement supports the NIH Blueprint Neurotherapeutics Network (BPN) for Small Molecules, specifically for participation in the BPN External Oversight Committee (EOC). The solicitation, identified as 7571PS27Q00021, is set aside exclusively for small business concerns under NAICS code 541690 (Other Scientific and Technical Consulting Services), with a small business size standard of $19 million. Purpose and Scope: The primary objective of this procurement is to engage two highly experienced executive-level advisors with expertise in Chemistry and/or Pharmacology. These SMEs will provide strategic feedback and technical guidance to NIH program leadership on drug discovery and development projects within the BPN portfolio. As members of the BPN External Oversight Committee, the advisors will contribute to the oversight and direction of BPN projects and, as needed, other NIH drug discovery and development initiatives. The role is critical in ensuring that NIH’s neurotherapeutic programs benefit from industry-leading expertise and maintain alignment with best practices in drug development. Key Requirements and Deliverables: Contractors must demonstrate substantial experience in drug discovery and development, with a focus on small molecule therapeutics. The scope of work includes: - Providing expert feedback and recommendations to NIH leadership on ongoing and proposed BPN projects. - Participating in EOC meetings and offering strategic guidance on project selection, progress, and technical challenges. - Occasionally advising on other NIH drug discovery and development programs as requested. Offerors must submit resumes and letters of commitment for proposed key personnel, ensuring that all key personnel are employed by the offeror at the start of the contract. A narrative detailing how the proposed personnel meet the evaluation criteria is required, in addition to past performance examples relevant to similar work. The government anticipates an estimated 50 labor hours per year per advisor, with an option for up to an additional 50 hours annually. Travel expenses, up to $2,000 per consultant per year, may be reimbursed if deemed necessary and pre-approved by the government. Contract Structure and Terms: The anticipated contract will be a fixed-price purchase order, with a base period of performance from November 5, 2026, to November 4, 2027, and two option years extending through November 4, 2029. The total contract duration, including options, will not exceed three years. The government reserves the right to make one award, multiple awards, or no award, based on the evaluation of offers. The solicitation incorporates standard FAR and HHSAR provisions and clauses, including requirements for key personnel management, options for increased quantity, and contract extension terms. Notably, salary rates for personnel must not exceed the Executive Schedule, Level II, as defined by NIH policy. All offerors must be actively registered in the System for Award Management (SAM) at the time of quote submission. Evaluation Criteria: Quotations will be evaluated based on technical capability, price, and past performance. Technical responses must provide clear evidence of personnel qualifications, including detailed resumes and a narrative addressing the evaluation criteria. Price proposals must utilize the provided template and include a breakdown of labor rates, hours, and any other direct costs. Past performance submissions should highlight relevant projects, personnel, and demonstrate the offeror’s ability to deliver similar services. Administrative Details: The place of performance is Bethesda, Maryland. All responses must be submitted electronically by 1:00 PM Eastern Time on November 5, 2026, referencing solicitation number 7571PS27Q00021. Questions regarding the solicitation must also be submitted by this deadline. The primary points of contact are Ebony Chester ([email protected]) and Michelle Cecilia ([email protected], 301-272-9118). Contractors interested in this opportunity should review the full Statement of Work and associated attachments available via the SAM.gov notice (Opportunity ID: d4e55ffff26e437e805e948411118563). This procurement represents a significant opportunity for small businesses with deep expertise in scientific and technical consulting for drug discovery and development, particularly in the neurotherapeutics domain. Constant Elements: Throughout the contract lifecycle, the requirement for highly qualified senior advisors, adherence to NIH salary limitations, compliance with federal and HHSAR clauses, and the need for active SAM registration will remain unchanged. The place of performance, contract structure, and the strategic advisory role within the BPN EOC are also fixed elements of this opportunity. For further information and to access solicitation documents, visit: https://sam.gov/opp/d4e55ffff26e437e805e948411118563/view.
Documents10